BeiGene's Japanese approval signals that Chinese biotech companies can now compete in the world's most demanding regulatory markets, challenging the dominance of Western pharma giants.
BeiGene's Japanese approval signals that Chinese biotech companies can now compete in the world's most demanding regulatory markets, challenging the dominance of Western pharma giants.
Japanese MHLW approval for tislelizumab in non-small cell lung cancer
First Chinese-developed PD-1 inhibitor approved in Japan
Directly competes with Keytruda and Opdivo in the Japanese market
This approval in Japan, a leading APAC pharmaceutical market, signals a new era for Chinese biotech, validating its innovation and regulatory prowess. It sets a crucial precedent for other APAC biopharmaceutical companies, particularly those in South Korea and Singapore, aiming for market entry into highly regulated developed economies. This could intensify regional competition and foster more cross-border R&D collaborations within Asia.
First Chinese-developed PD-1 inhibitor approved in Japan
Directly competes with Keytruda and Opdivo in the Japanese market
Sign in to save notes on signals.
Sign In